Why Regado Biosciences (RGDO) Stock Is Nosediving 50% Today
August 25, 2014 at 09:10 AM EDT
Regado Biosciences Inc (RGDO) is one of Monday’s notable stocks in decline, down more than 50% after the company said it had terminated the late-stage trial testing of its lead program’s efficacy in fighting coronary artery disease. Regado Biosciences said the study’s data and safety-monitoring board “indicated that the level of serious allergic adverse events […] View the full post at: Why Regado Biosciences (RGDO) Stock Is Nosediving 50% Today Related posts: Congress To Hold Hearing on the Circumstances Behind Thursday’s Stock Market Plunge Casino capitalism on trial